Hypothesis

Chronic mTORC1 activation in aging neurons directly inhibits the transcription factor MEF2, reducing calbindin-D28k synthesis and compromising calcium buffering. This shifts neurons from a civilizational, growth‑oriented state to a survival‑deficient phenotype that predisposes them to excitotoxic degeneration.

Mechanistic Basis

mTORC1 phosphorylates and inhibits the histone deacetylase HDAC5, which normally facilitates MEF2 transcriptional activity by deacetylating MEF2 proteins. When mTORC1 is persistently active, HDAC5 remains phosphorylated and sequestered in the cytoplasm, preventing its nuclear import and thus keeping MEF2 in a repressed state. Consequently, the calbindin promoter receives less MEF2‑driven transcription, lowering calbindin protein levels. Reduced calbindin diminishes the neuron’s capacity to sequester rapid Ca²⁺ influx, prolonging intracellular calcium elevations after synaptic activity and increasing susceptibility to excitotoxic cascades.

This mechanism aligns with the civilizational‑versus‑survival dial concept: mTORC1‑driven anabolic programs prioritize ribosome biogenesis and protein synthesis for growth and synaptic plasticity, while simultaneously downregulating stress‑responsive proteins like calbindin that are essential for long‑term maintenance. Caloric restriction or rapamycin treatment, by inhibiting mTORC1, would allow HDAC5 deacetylation, nuclear accumulation, and MEF2 reactivation, thereby restoring calbindin expression and calcium homeostasis.

Predictions & Experimental Design

1. Phospho‑HDAC5 and nuclear HDAC5 levels – In aged mouse basal forebrain cholinergic neurons, phospho‑HDAC5 will be elevated and nuclear HDAC5 reduced compared with young adults. Rapamycin treatment will decrease phospho‑HDAC5 and increase nuclear HDAC5.
2. MEF2 transcriptional activity – A MEF2‑responsive luciferase reporter will show reduced activity in aged neurons, rescued by rapamycin or HDAC5 overexpression.
3. Calbindin expression – Western blot and immunofluorescence will reveal a 40‑60% drop in calbindin‑D28k in aged neurons; rapamycin administration for 4 weeks will restore levels to ≥80% of young controls.
4. Calcium buffering capacity – Fluorescent calcium imaging after a brief glutamate pulse will demonstrate slower Ca²⁺ clearance (τ increased 4‑5×) in aged neurons; rapamycin will normalize τ to youthful values.
5. Neuronal survival – Cultured aged neurons exposed to excitotoxic glutamate will exhibit higher caspase‑3 activation; rapamycin pretreatment will reduce cell death by ≥30%.

Experimental groups (n=8 mice per group): young vehicle, aged vehicle, aged rapamycin (0.5 mg/kg i.p. every other day for 4 weeks), aged rapamycin + MEF2 inhibitor (to test specificity). Outcomes measured as above.

Potential Outcomes & Falsifiability

• If rapamycin increases nuclear HDAC5, MEF2 activity, calbindin expression, and calcium clearance while protecting neurons, the hypothesis is supported.
• If rapamycin fails to alter HDAC5 phosphorylation or nuclear localization yet still improves calcium handling, the proposed HDAC5‑MEF2 axis is insufficient, falsifying this specific mechanism.
• If MEF2 inhibition blocks rapamycin’s calbindin‑raising effect, it confirms MEF2 as a necessary downstream effector.
• Conversely, if calbindin levels remain low despite restored MEF2 activity, alternative mTORC1‑dependent pathways (e.g., enhanced proteasomal degradation) must be considered, prompting refinement of the model.

This framework directly links mTORC1 signaling to a concrete molecular switch governing calcium‑buffering capacity, offering a testable bridge between the longevity‑extending effects of mTOR inhibition and the preservation of neuronal resilience in aging.